Efficacy and safety of Etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy

We report one case of pregnancy-onset severe diffuse proliferative nephritis in a patient with systemic lupus erythematosus (SLE), who was successfully treated with a combination of anti-tumour necrosis factor (TNF)-alpha, plasmapheresis and high-dose intravenous gammaglobulin. No flares were observ...

Full description

Saved in:
Bibliographic Details
Published in:Lupus 2006-01, Vol.15 (12), p.881-885
Main Authors: Micheloud, D, Nuño, L, Rodríguez-Mahou, M, Sánchez-Ramón, S, Ortega, M C, Aguarón, A, Junco, E, Carbone, J, Fernández-Cruz, E, Carreño, L, López-Longo, F J
Format: Article
Language:English
Subjects:
Adult
Combined Modality Therapy
Etanercept
Female
Humans
Immunoglobulin G - administration & dosage
Immunoglobulin G - adverse effects
Immunoglobulins, Intravenous
Immunosuppressive Agents - administration & dosage
Immunosuppressive Agents - adverse effects
Infant, Newborn
Lupus Nephritis - drug therapy
Male
Plasmapheresis
Pregnancy
Pregnancy Complications - drug therapy
Pregnancy Outcome
Receptors, Tumor Necrosis Factor - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report one case of pregnancy-onset severe diffuse proliferative nephritis in a patient with systemic lupus erythematosus (SLE), who was successfully treated with a combination of anti-tumour necrosis factor (TNF)-alpha, plasmapheresis and high-dose intravenous gammaglobulin. No flares were observed either in clinical symptoms or in laboratory examinations during pregnancy or after delivery. Her autoantibodies except fluorescent anti-nuclear antibodies were negative. We suggest that a combination of anti-TNF-alpha, plasmapheresis and high-dose intravenous gammaglobulin may be a safe and effective therapy for pregnant patients suffering severe lupus nephritis.
ISSN:0961-2033
1477-0962
DOI:10.1177/0961203306070970